Pharmaceuticals News and Research

RSS
Dyadic International's total revenue for Q1 2014 up 20%

Dyadic International's total revenue for Q1 2014 up 20%

First Edition: May 8, 2014

First Edition: May 8, 2014

IPM gains exclusive worldwide rights to promising HIV prevention medicine from Janssen R&D Ireland

IPM gains exclusive worldwide rights to promising HIV prevention medicine from Janssen R&D Ireland

Viewpoints: Evidence for Obamacare saving lives; a continuing role for Minnesotacare

Viewpoints: Evidence for Obamacare saving lives; a continuing role for Minnesotacare

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

New e.p.t Preconception Health Test to be available for reducing risk of preterm labor

New e.p.t Preconception Health Test to be available for reducing risk of preterm labor

Rigel Pharmaceuticals reports net loss of $22.3 million for first quarter 2014

Rigel Pharmaceuticals reports net loss of $22.3 million for first quarter 2014

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

LifeMap Solutions focuses on creating innovative mobile health products

LifeMap Solutions focuses on creating innovative mobile health products

Phillips-Medisize enters into definitive agreement with Golden Gate Capital

Phillips-Medisize enters into definitive agreement with Golden Gate Capital

Targacept reports net loss of $11.6M in first quarter 2014

Targacept reports net loss of $11.6M in first quarter 2014

ARIAD provides update on corporate developments, reports Q1 2014 financial results

ARIAD provides update on corporate developments, reports Q1 2014 financial results

Biovision's program to focus on economic, business challenges faced by life sciences industry

Biovision's program to focus on economic, business challenges faced by life sciences industry

New project aims to find better weapons against life-threating multi-resistant bacteria

New project aims to find better weapons against life-threating multi-resistant bacteria

Cumberland launches new Vaprisol product

Cumberland launches new Vaprisol product

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

Novel bioinformatics approach suggests antimicrobial drug may help in treating advanced kidney cancer

Novel bioinformatics approach suggests antimicrobial drug may help in treating advanced kidney cancer

Loxo Oncology announces closing of $24 million Series B private financing round

Loxo Oncology announces closing of $24 million Series B private financing round

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Naurex's two lead antidepressant programs achieve major milestones

Naurex's two lead antidepressant programs achieve major milestones

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.